Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece un tratamiento preventivo y terapéutico contra alergias y trastornos autoinmunitarios

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20180720003
Publicado:
24/07/2018
Caducidad:
25/07/2019
Resumen:
Una oficina francesa de transferencia de tecnología ofrece un nuevo tratamiento contra alergias y trastornos autoinmunitarios, como esclerosis múltiple, asma, dermatitis atópica, etc. Esta nueva tecnología se basa en partículas similares a virus (VLP), que inhiben la activación de células inmunitarias (células T y células presentadoras de antígeno como macrófagos, células B y células dendríticas). La oficina busca compañías farmacéuticas o biotecnológicas con el fin de establecer acuerdos de licencia o cooperación en materia de investigación.

Details

Tittle:
A French Technology Transfer Office offers a preventive and therapeutic treatment against allergies and auto-immune disorder
Summary:
A French Technology Transfer Office (TTO) offers a new treatment against allergies and auto-immune disorder . This new technology is based on VLPs (pseudo-Virus Like Particle).
The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a research cooperation agreement.
Description:
A French Technology Transfer Office (TTO) is acting on behalf of major life science research labs in Paris region, has designed and patented pseudo-viral like particles (VLPs) to prevent and cure allergy or auto-immune diseases like multiple sclerosis, asthma, atopic dermatisis ...

* Market challenges :
Auto-immune and allergic disease prevalence has significantly increased in developed countries these last few decades. They are the result of a bad immune system response. Even if many drugs are available to treat symptoms, there is no treatment to cure those diseases.
Treatments against auto-immune diseases rely on the use of immunosuppressive drugs, acting in a non-specific manner on the immune system, which have many unwanted consequences.
Allergy results from dysfunction of the immune system, and hypersensitivity caused by the environment leads to chronic forms of allergic inflammations.

Nowadays, there is no efficient way to sustainably treat allergy or immune dysfunctions. The development of new effective and specific treatments still remains necessary.

* State of the art :
VLPs resemble viruses, but are non-infectious because they contain no viral genetic material. The expression of viral structural proteins, such as envelope or capsid proteins, can result in the self-assembly of virus like particles. Attaching proteins, nucleic acids, or small molecules to the VLP surface, such as for targeting a specific cell type or for raising an immune response could be useful.

* Proposed technology :
The French researchers have designed VLPs which are able to inhibit immune cell activation (T cells and Antigen-presenting cells like macrophages, B cells and dendritic cells) . The particularity is that these VLPs express an immunoregulator molecule at the surface, prone to recruit suppressive Treg cells.
These particles can be used to modify, regulate or inhibit the immune responses. More precisely, these particles restore the immune tolerance towards specific antigens and can be used to treat immune dysfunction such as allergy.

*partnership :
The partner sought could be a company interested in :
- a license agreement (the TTO is able to negotiate directly the intellectual property transactions for specific applications), or
- a research cooperation agreement in order to investigate new diseases to target.

*Keywords :
#allergic diseases
#vaccine
#vlp
#autoimmune disease
#multiple sclerosis
Advantages and Innovations:
The advantages of this new technology are:

· VLPs regulate the immune system in a long lasting and in a specific manner
· VLPs can be specifically designed to provide a specific cure for every disease when the antigen responsible for the disease is known allowing personalized therapy
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT patent application filed in 2017.

Partner sought

Type and Role of Partner Sought:
The partner sought could be:
-a company involved in the field of allergy interested in developing some more efficient therapeutic solutions or,
-a company developing immunomodulation strategies.
This technology could interest drugs formulation companies or commercializing companies (pharma or biotech).

Research cooperation agreement: the potential industrial partner should be interested to invest in co-development for another specific food allergy (milk, fish,...) or auto-immune desease. A research agreement between the laboratory and a company can be partially funded by the TTO.

License agreement: the potential industrial partner should be interested in negotiating a license agreement in order to commercialize a new drug using the patented VLP´s (after launching clinical trials).

Client

Type and Size of Client:
Industry SME 50-249
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002004 Ingeniería de proteínas
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología